Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.83 |
| ▸ | ABL1 | P00519 | 2/20 | 0.83 |
| ▸ | ABL2 | P42684 | 1/20 | 0.83 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.83 |
| ▸ | RAF1 | P04049 | 1/20 | 0.72 |
| ▸ | BRAF | P15056 | 1/20 | 0.72 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743898 | 0.92 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL5733387 | 0.91 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL938436 | 0.91 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2616949 | 0.91 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2083328 | 0.90 | MAPK14 (0.85) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2080630 | 0.89 | MAPK14 (0.85) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2081138 | 0.88 | MAPK14 (0.84) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2083472 | 0.88 | MAPK14 (1.00) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2084072 | 0.88 | MAPK14 (0.81) | MAPK14MAPK11ABL1ABL2MAPK8 | |
| SCHEMBL2083771 | 0.87 | MAPK14 (0.84) | MAPK14MAPK11ABL1ABL2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| EP-1056725-B1 | INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-07 | — | — | EP | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885ABL1 183/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885ABL1 183/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885ABL1 183/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885ABL1 183/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | MAPK14 380/4885MAPK11 246/4885ABL1 272/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885MAPK11 124/4885ABL1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.